Health
Diabetes and weight-loss drug ‘changed my life,’ says senator: ‘I feel a decade younger’
A U.S. senator said a GLP-1 drug changed his life — and now he’s calling for widespread access to anti-obesity medications.
In a New York Times op-ed on April 8, Sen. John Fetterman, D-Pa., wrote about his experience with Mounjaro (tirzepatide).
The injectable prescription medicine is primarily used to treat type 2 diabetes.
OZEMPIC’S HEALTH BENEFITS KEEP GROWING, BUT ARE THE RISKS WORTH IT?
Fetterman was prescribed the medication in July 2024.
“As a stroke survivor, I was interested in studies showing [Mounjaro] could significantly reduce the risk of major cardiac events,” the senator wrote.
Sen. John Fetterman, D-Pa., walks to the chamber on Capitol Hill in Washington, D.C., on March 14, 2025. In an op-ed on April 8, the Pennsylvania senator wrote about his experience with Mounjaro (tirzepatide). (Reuters)
“Even though I started taking it for my heart health, I’ve been struck by how much better it has made me feel across the board. It’s made a significant impact on my overall health,” he continued.
“Aches, pains and stiffness have vanished. Physically, I feel a decade younger, as well as clearer-headed and more optimistic than I’d been in years. As far as side effects, I’ve also lost around 20 pounds.”
GENETIC CHOLESTEROL ELIMINATED BY NEW DRUG, REDUCING HEART ATTACK RISK, STUDY FINDS
Beyond lowering blood sugar, GLP-1 medications have also been linked to a range of other benefits, including improved heart health, neurological function and metabolic health, as Fox News Digital has reported.
Eli Lilly, maker of Mounjaro, also offers another version of the drug called Zepbound, which is the same medication approved for weight loss, chronic weight management and sleep apnea.
Other GLP-1 medications include Ozempic, Wegovy, Victoza, Saxenda, all made by Novo Nordisk.
Sen. Fetterman is pictured at the White House on Jan. 29, 2025. “As a stroke survivor, I was interested in studies showing [Mounjaro] could significantly reduce the risk of major cardiac events,” the senator wrote in an April op-ed. (Reuters)
Fetterman noted that GLP-1 drugs have been found to have beneficial effects on cholesterol, heart rate and heart inflammation.
“Some recent studies suggest they might even help curb alcohol addiction and support cognitive function, potentially slowing or preventing conditions like Parkinson’s and Alzheimer’s,” he wrote in the Times op-ed.
“Physically, I feel a decade younger, as well as clearer-headed and more optimistic than I’d been in years.”
In the op-ed, Fetterman called for expanded access to these medications, which can cost up to $1,000 out of pocket if not covered by insurance.
“Currently, Medicare covers these drugs only under specific circumstances, such as for diabetes or heightened heart risk,” he wrote. “And Medicaid coverage is even more limited.”
Fetterman added that he was not compensated for sharing his experience.
OZEMPIC ‘MICRODOSING’ IS THE NEW WEIGHT-LOSS TREND
“I’m just a guy who has benefited from these medications and wants to make sure that anyone else who could benefit from them can have access to them, too,” he wrote.
While Fetterman shares HHS Sec. Robert F. Kennedy Jr.’s views of prioritizing nutrition and healthy living, he said he believes the medications are necessary for some.
Eli Lilly, maker of Mounjaro, also offers another version of the drug called Zepbound, which is the same medication approved for weight loss, chronic weight management and sleep apnea. (iStock)
“I fully agree that diet and lifestyle matter — a lot. But diet alone isn’t enough,” he wrote.
“For the millions of Americans struggling with serious health issues, medication can be a crucial first step to regaining enough control of their health to begin making meaningful lifestyle changes.”
Doctors discuss benefits and access
Dr. Marc Siegel, clinical professor of medicine at NYU Langone Health and Fox News’ senior medical analyst, noted that semaglutides, including Ozempic and Wegovy, are “very important drugs” for type 2 diabetes, with increasing use for obesity.
“Though these drugs appear to have beneficial uses for the heart and lipid profile — and also the brain and decreasing dementia risk — studies are ongoing and more data is still needed,” he told Fox News Digital.
The first approach to obesity is lifestyle changes, including exercise, improved diet and optimal sleep, Siegel said.
“Having said that, these weight-loss drugs (including Zepbound) are also good tools when lifestyle is not enough,” he noted.
Fetterman was prescribed Mounjaro for potential heart health benefits. (Getty Images)
“They help prevent down-the-line diseases such as heart disease, stroke, high blood pressure and sleep apnea, which tend to come from obesity.”
He added, “Overall, we are saving the healthcare system money, so I would like to see Medicare and Medicaid approve them for diabetes and weight loss.”
CLICK HERE TO SIGN UP FOR OUR HEALTH NEWSLETTER
Dr. Brett Osborn, a Florida neurologist and longevity expert, said he’s been prescribing GLP-1s to his patients since 2019.
“Mounjaro and its cousins aren’t just weight-loss tools — they’re metabolic reset buttons,” he told Fox News Digital.
Beyond lowering blood sugar, GLP-1 medications have also been linked to a range of other benefits, including improved heart health, neurological function and metabolic health. (iStock)
“People with metabolic syndrome don’t need lectures on kale and the importance of exercise. They need help.”
Osborn agreed that lifestyle is essential, but is “rarely sufficient.”
“GLP-1s give patients momentum by getting the ball rolling,” he said. “And when that happens, health habits are formed. Diet improves. Movement improves. People start to feel the benefits of healthy living.”
For more Health articles, visit www.foxnews.com/health
Osborn noted that these medications aren’t cosmetic, but therapeutic.
“I’ve seen what they can do firsthand: reductions in body fat, inflammation, glucose, triglycerides and insulin resistance — and with those, significant reductions in the incidence of stroke and heart attack.”
“I believe this is a signal aimed squarely at Big Pharma.”
President Donald Trump’s administration recently announced that Medicare and Medicaid would not cover the medications, as the Centers for Medicare and Medicaid Services said late Friday.
Osborn said the move to block coverage likely doesn’t have to do with efficacy.
“Trump knows these medications work,” Osborn said. “I believe this is a signal aimed squarely at Big Pharma: ‘Lower the price, or Medicare, the biggest buyer on the block, is out.’”
“This isn’t a dismissal — it’s leverage,” Osborn said, stating his opinion on the matter. “President Trump will likely negotiate until the ‘price is right,’ disempowering Big Pharma while concomitantly bettering the health of Americans.”
Fox News Digital reached out to Fetterman’s office for comment.
Health
4 Mistakes People Make When Starting a GLP-1 That Can Stall Weight Loss—Plus How to Maximize Your Results
Use left and right arrow keys to navigate between menu items.
Use escape to exit the menu.
Sign Up
Create a free account to access exclusive content, play games, solve puzzles, test your pop-culture knowledge and receive special offers.
Already have an account? Login
NEWYou can now listen to Fox News articles!
With an aggressive new strain spreading across the country, this year’s flu season has been marked by record-high hospitalizations and reportedly intense symptoms.
As people look for ways to contain the spread, new research has found that a few simple factors can greatly reduce transmission.
Researchers from the University of Maryland Schools of Public Health and Engineering in College Park and the School of Medicine in Baltimore studied influenza spread by placing flu-positive college students in a hotel room with healthy middle-aged adult volunteers.
FLU HOSPITALIZATIONS HIT ALL-TIME WEEKLY HIGH IN DENSELY POPULATED STATE, OFFICIALS WARN
The study, published in the journal PLOS Pathogens, is reportedly the first clinical trial investigating how the flu spreads from naturally infected people to uninfected people, according to a press release.
The participants, including 11 healthy volunteers, lived on a quarantined floor of a Baltimore-area hotel for two weeks. During that time, they simulated interactions, including having conversations, doing physical activities like yoga, and passing around objects like pens and tablets from infected people to the rest of the group.
New research has experts questioning how the flu spreads through airborne transmission. (iStock)
Researchers monitored the participant’s symptoms, performed daily nasal swabs, and collected saliva and blood samples to test for antibodies, the release stated.
The study also measured the “viral exposure” in the volunteers’ breathing air and ambient air in the activity room. The exhaled breath of the participants was measured by a machine called the Gesundheit II, invented by researcher Dr. Donald Milton and colleagues at Harvard T.H. Chan School of Public Health.
COULD DENTAL FLOSS BE THE NEXT VACCINE METHOD? SCIENTISTS SAY IT COULD WORK
At the end of the experiment, none of the healthy individuals had become infected with the flu due to a variety of factors. This included a lack of coughing, as the infected students were holding “a lot of virus in their noses” and only small amounts were “expelled into the air,” the researchers noted.
Researchers said proper ventilation was a major factor in halting flu spread in this study. (iStock)
“Our data suggests key things that increase the likelihood of flu transmission — coughing is a major one,” Dr. Jianyu Lai, post-doctoral research scientist and the study’s lead data analyst and report writer, shared in a statement.
CLICK HERE FOR MORE HEALTH STORIES
The other factor was ventilation and air movement, as the air in the study room was “continually mixed rapidly by a heater and dehumidifier, and so the small amounts of virus in the air were diluted,” Lai pointed out.
The researcher added that middle-aged adults are “usually less susceptible” to influenza than younger adults.
CLICK HERE TO SIGN UP FOR OUR HEALTH NEWSLETTER
Most researchers assume that airborne transmission is a major factor of disease spread, according to Dr. Donald Milton, professor at SPH’s Department of Global, Environmental and Occupational Health and a global infectious disease aerobiology expert.
“At this time of year, it seems like everyone is catching the flu virus, and yet our study showed no transmission,” he said in the same press release. “What does this say about how flu spreads and how to stop outbreaks?”
There have been 81,000 flu-related hospitalizations and more than 3,000 deaths in the U.S. this year so far, data shows. (iStock)
Milton, who was reportedly among the first experts to identify how to stop the spread of COVID-19, noted that findings from these types of trials are essential to updating international infection-control guidelines.
CLICK HERE TO DOWNLOAD THE FOX NEWS APP
“Being up close, face-to-face with other people indoors where the air isn’t moving much, seems to be the most risky thing — and it’s something we all tend to do a lot,” he said.
“At this time of year, it seems like everyone is catching the flu virus, and yet our study showed no transmission.”
“Our results suggest that portable air purifiers that stir up the air, as well as clean it, could be a big help,” Milton suggested. “But if you are really close and someone is coughing, the best way to stay safe is to wear a mask, especially the N95.”
TEST YOURSELF WITH OUR LATEST LIFESTYLE QUIZ
Approximately 11 million flu illnesses and about 5,000 deaths have occurred so far in the 2025-2026 influenza season, according to CDC data. A large share of the current flu cases are caused by the new influenza A subclade K variant.
NEWYou can now listen to Fox News articles!
GLP-1 has become a popular buzzword in the weight-loss community — but now some are touting “GLP-3s,” claiming they are taking obesity medications to the next level.
GLP-1 (glucagon-like peptide-1) medications work by mimicking a naturally occurring hormone in the body that helps regulate blood sugar and appetite.
The informal term “GLP-3” refers to a new triple-agonist drug that targets three hormones: GLP-1, GIP (glucose-dependent insulinotropic polypeptide, another naturally occurring hormone released by the gut after eating) and glucagon receptors. The most advanced example is retatrutide by Eli Lilly, according to clinical trial outcomes.
OBESITY EXPERT REVEALS THE BEST WAY TO DECIDE IF GLP-1S ARE RIGHT FOR YOU
The New England Journal of Medicine published results from a 2023 phase 2 retatrutide trial for obesity, revealing “substantial reductions in body weight” after 48 weeks of treatment.
A 12 mg once-weekly injection led to a 24.2% weight reduction, and participants continued to drop pounds after the 48-week trial period.
GLP-1 (glucagon-like peptide-1) medications work by mimicking a naturally occurring hormone in the body that helps regulate blood sugar and appetite. (iStock)
Side effects were reportedly similar to GLP-1 medications, most commonly including gastrointestinal complications like nausea, vomiting and diarrhea. Heart rate increases were noted, depending on the dose.
How it’s different
Retatrutide mimics three natural hormones found in the body, compared to GLP-1s that simulate just one hormone, according to a report by GoodRx pharmacists.
GIP and GLP-1 hormones signal the pancreas to release insulin after eating, while slowing digestion to help initiate feelings of fullness.
NEW WEGOVY PILL OFFERS NEEDLE-FREE WEIGHT LOSS — BUT MAY NOT WORK FOR EVERYONE
These hormones target the area of the brain that regulates appetite and influences food cravings, the report noted.
The third hormone, glucagon, speeds up metabolism and helps the body break down fat cells for energy. That hormone also tells the liver to make new sugar, which is kept in check by GIP and GLP-1 activity, preventing blood sugar spikes.
Participants in the phase 3 trial saw an average weight loss of 71.8 pounds. (iStock)
“This added metabolism boost can add to and complement GIP’s and GLP-1’s actions. And that’s why it seems to provide significant weight loss,” the GoodRx website states. “If approved, retatrutide will be the first in a new class of medications.”
Eli Lilly announced results from its phase 3 trial TRIUMPH-4 in December, testing retatrutide’s effect on weight loss and other health conditions.
“We believe retatrutide could become an important option for patients with significant weight loss needs and certain complications.”
Participants with obesity and knee arthritis who took a 12-mg dose of retatrutide saw an average weight loss of 71.8 lbs (28.7%) at 68 weeks.
“For retatrutide, the findings from TRIUMPH-4 are encouraging, and with seven additional phase 3 readouts expected in 2026, we believe retatrutide could become an important option for patients with significant weight loss needs and certain complications, including knee osteoarthritis,” a Lilly spokesperson said in a statement to Fox News Digital.
CLICK HERE FOR MORE HEALTH STORIES
The drug also reduced Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) pain scores by an average of 75.8%, marking “significant improvements” in comfort level and physical function.
More than one in eight patients reported being “completely free” from knee pain at the end of the trial, according to a press release from Lilly.
Participants with obesity and knee arthritis who took a 12-mg dose of retatrutide saw an average weight loss of 71.8 lbs (28.7%) at 68 weeks. (iStock)
Seven additional phase 3 trials for retatrutide are expected to wrap up in 2026. The drug could see FDA approval in 2027, according to GoodRx.
The Lilly spokesperson noted that there have been no studies comparing retatrutide to GLP-1 treatments due to “differences in study design and patient populations.”
CLICK HERE TO DOWNLOAD THE FOX NEWS APP
Despite limited data availability on the drug, the medication could also be applied to treat other conditions like type 2 diabetes, kidney disease, cardiovascular risk reduction and metabolic dysfunction, according to GoodRx and other experts.
Fox News senior medical analyst Dr. Marc Siegel noted that Lilly’s Zepbound and Mounjaro already target two metabolic pathways — GLP-1 and GIP — which work together to promote weight loss, reduce hunger and inflammation, improve insulin function and slow digestion.
The doctor confirmed that the new drug, with its third receptor agonist, will further decrease hunger while increasing the feeling of fullness.
More than one in eight patients reported being “completely free” from knee pain at the end of the trial. (iStock)
“The weight loss in clinical trials is even more substantial, and the most likely reason that it decreases orthopedic problems is because of the weight loss — less stress on the joints and the decreased inflammation,” Siegel added.
CLICK HERE TO SIGN UP FOR OUR HEALTH NEWSLETTER
The most common side effect of GLP-3s is gastrointestinal symptoms, the doctor confirmed. Rarer side effects may include pancreatitis, gallstones and heart arrhythmia.
TEST YOURSELF WITH OUR LATEST LIFESTYLE QUIZ
Philip Rabito, M.D., a specialist in endocrinology, weight loss and wellness in New York City, shared in an interview with Fox News Digital that this new class of weight-loss drugs is positioned to “approach bariatric surgery level outcomes” — although it doesn’t come without risks.
“The novel glucagon‑agonist component introduces less‑understood long‑term safety considerations, so it is imperative that patients are followed closely by healthcare professionals experienced with this class of medicines, with cautious, stepwise use, despite the impressive efficacy,” he cautioned.
WATCH: Horse-mounted officers capture previously deported child predator at border
DeSantis launches Florida redistricting push to potentially add more GOP House seats
Federal judge disqualifies US attorney, tosses subpoenas targeting NY AG Letitia James
Video: New York City Nurses Go on Strike
Detroit Auto Show opens as industry pares back splashy debuts and leans on test tracks
Florida High School Football Rankings: Top 25 teams – Oct. 21
Cleary's 21 help Le Moyne down Central Connecticut State 69-64 in OT
How old is Bo Nix? What to know about Oregon quarterback ahead of 2024 NFL Draft
99th annual Pony Swim held in Virginia
Video: ‘It Didn’t Have to Happen This Way:’ U.Va. Faculty Call for Review of Police Response to Protests
Rep Ro Khanna demands prosecution of ICE agent in Minneapolis fatal shooting
Syrian army sends troops to rural Aleppo to stop any SDF attempt to regroup
Iran acknowledges mass protest deaths, but claims situation under control as Trump mulls response
The Mayor of London explains why he thinks London is getting safer | BBC Newscast
Video: What Our Photographer Saw in Minneapolis
-
Detroit, MI1 week ago2 hospitalized after shooting on Lodge Freeway in Detroit
-
Technology7 days agoPower bank feature creep is out of control
-
Montana3 days agoService door of Crans-Montana bar where 40 died in fire was locked from inside, owner says
-
Delaware4 days agoMERR responds to dead humpback whale washed up near Bethany Beach
-
Dallas, TX5 days agoAnti-ICE protest outside Dallas City Hall follows deadly shooting in Minneapolis
-
Dallas, TX1 week agoDefensive coordinator candidates who could improve Cowboys’ brutal secondary in 2026
-
Iowa7 days agoPat McAfee praises Audi Crooks, plays hype song for Iowa State star
-
Virginia3 days agoVirginia Tech gains commitment from ACC transfer QB